Clinical Trials
Source: CCM
- Score: 8Phase 1 Cancers
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Score: 6Kidney Cancer, Melanoma
XTX301 in Patients With Advanced Solid Tumors
- Score: 5Colorectal Cancer, Pancreatic Cancer
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Selected Solid Tumors
- Score: 4Phase 1 Cancers
Study of ARTS-021 in Patients With Advanced Solid Tumors
- Score: 3Phase 1 Cancers
An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors